Janney Montgomery Scott LLC Purchases 21,229 Shares of AbbVie Inc. $ABBV

Janney Montgomery Scott LLC boosted its position in shares of AbbVie Inc. (NYSE:ABBV) by 2.3% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 960,158 shares of the company’s stock after buying an additional 21,229 shares during the quarter. Janney Montgomery Scott LLC owned approximately 0.05% of AbbVie worth $222,315,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Marshall & Sullivan Inc. WA purchased a new stake in AbbVie in the 2nd quarter worth approximately $25,000. Evolution Wealth Management Inc. bought a new position in shares of AbbVie during the second quarter valued at approximately $26,000. Spurstone Advisory Services LLC bought a new position in shares of AbbVie during the second quarter valued at approximately $28,000. Financial Gravity Companies Inc. purchased a new stake in AbbVie in the second quarter worth $36,000. Finally, Delos Wealth Advisors LLC bought a new stake in AbbVie in the second quarter valued at $39,000. 70.23% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have commented on ABBV. DZ Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective for the company. in a report on Tuesday, November 4th. UBS Group began coverage on shares of AbbVie in a research note on Wednesday. They issued a “neutral” rating and a $240.00 price target for the company. Bank of America lifted their price objective on AbbVie from $220.00 to $251.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Berenberg Bank upgraded AbbVie from a “hold” rating to a “buy” rating and raised their target price for the company from $170.00 to $270.00 in a research note on Wednesday, September 17th. Finally, Guggenheim lifted their price target on AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a research report on Monday, October 20th. Three analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $246.89.

AbbVie Stock Down 1.8%

Shares of ABBV opened at $220.06 on Monday. The stock has a market cap of $388.93 billion, a P/E ratio of 166.71, a P/E/G ratio of 0.92 and a beta of 0.36. The business’s 50 day moving average price is $226.59 and its 200-day moving average price is $215.53. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. The business had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The firm’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, equities analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be paid a $1.73 dividend. This is a boost from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a dividend yield of 3.1%. The ex-dividend date is Friday, January 16th. AbbVie’s payout ratio is currently 496.97%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.